Bladder CancerNCT05082818
Outcome of Treating Bladder Cancer in Sohag University Hospital
An observational study of Bladder Cancer, run by Sohag University at 1 site in Egypt.
Trial summary
Retrospective study of outcome of urinary bladder cancer treated in Sohag University hospital in the past 5 years from 2016 to 2020 Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Bladder Cancer
- What is being tested?
- Chemotherapy, Radiotherapy and surgery
- How many people
- 168 participants
- Where
- 1 siteEgypt
- Study dates
- 30 Oct 2021to 30 May 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- Adult, Older adult
Study population: Bladder cancer patients of both sex and aged from 18 to 80 years old
Who may be able to join
- all stages and grades of urinary bladder cancer Any histological types of urinary bladder cancer
Who cannot join
- presence of other malignancies
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Outcome of Treating Urinary Bladder Cancer in Sohag University Hospital Between 2016 to 2020
Retrospective study of outcome of urinary bladder cancer treated in Sohag University hospital in the past 5 years from 2016 to 2020
Read the detailed description
This study asses the risk factors, prognosis,disease free survival and overall survive rate of treating urinary badder cancer
- Conditions
- Bladder Cancer
- Being tested
- Chemotherapy, Radiotherapy and surgery
- Medical subject headings
- Urinary Bladder Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Chemotherapy, Radiotherapy and surgeryCombination product
Trans urethral resection of the tumour or radical cystectomy
What is being measured
The primary outcome is the main question the study is designed to answer.
Disease free survival
Time from the end of treatment to the date of first relapse
Measured: 2 weeks after treatment to the time of relapse
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Oct 2021
- Study start30 Oct 2021
- Primary completion28 May 2022
- Study completion30 May 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bladder CancerStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 168 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Samah Refat Ahmed, Sohag University
- Investigators
- Samah Refaat, Principal investigator, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05082818
- Sponsor's protocol ID
- Soh-Med-21-10-16
- Status last verified
- Jun 2022
- First submitted
- 15 Oct 2021
- Last updated
- 14 Jun 2022
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 14 Jun 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Outcome of Treating Urinary Bladder Cancer in Sohag University Hospital Between 2016 to 2020
- ClinicalTrials.gov ID
- NCT05082818
- Acronym / sponsor ID
- Soh-Med-21-10-16
- Conditions
- Bladder Cancer
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 168 participants (actual)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 30 Oct 2021 (actual)
- Primary completion
- 28 May 2022 (actual)
- Study completion
- 30 May 2022 (actual)
- First posted
- 19 Oct 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Retrospective study of outcome of urinary bladder cancer treated in Sohag University hospital in the past 5 years from 2016 to 2020
Detailed description
This study asses the risk factors, prognosis,disease free survival and overall survive rate of treating urinary badder cancer
Study design
- Observational model
- Other
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Bladder cancer patients of both sex and aged from 18 to 80 years old
Key inclusion criteria (1 listed)
- all stages and grades of urinary bladder cancer Any histological types of urinary bladder cancer
Key exclusion criteria (1 listed)
- presence of other malignancies
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Chemotherapy, Radiotherapy and surgeryTrans urethral resection of the tumour or radical cystectomy | Combination product | – |
Primary outcome
Disease free survival
Time frame: 2 weeks after treatment to the time of relapse
Time from the end of treatment to the date of first relapse
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jun 2022.
- Individual participant dataSharing planned: Undecided
Related trials for Bladder Cancer
RecruitingPhase 2/3
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma
RecruitingPhase 3
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)
Bladder Cancer
Active, not recruitingPhase 2/3
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Biliary Tract Cancer, Cholangiocarcinoma
Recruiting
Effect of Cyclic Sighing Breathing Exercise on CRBD, Pain, and Sleep Quality in Patients Undergoing TUR
Transurethral Resection of Bladder Tumor, Transurethral Resection of the Prostate (TURP)
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Samah Refaat principal investigator
Sohag University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Bladder Cancer, run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Jun 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Disease free survival (time frame: 2 weeks after treatment to the time of relapse). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jun 2022.